Gastric Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GST053 MIFTS: 77	Gastric Cancer Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer ⁵⁷ ³⁸ ¹² ⁵³ ⁷⁵ ³⁷ ⁵⁵

Stomach Cancer ¹² ⁷⁶ ⁵³ ⁷⁵ ²⁹ ⁴³ ¹⁵

Stomach Carcinoma ¹² ⁵³ ¹⁵ ⁷³

Malignant Tumor of Lesser Curve of Stomach ¹² ⁷³

Malignant Neoplasm of Body of Stomach ¹² ⁷³

Neoplasm of Stomach ²⁹ ⁶

Gastric Carcinoma ¹² ⁵⁵

Stomach Neoplasms ⁴⁴ ⁷³

Malignant Neoplasm of Lesser Curve of Stomach ¹²

Malignant Tumor of Greater Curve of Stomach ¹²

Malignant Tumor of Body of Stomach ¹²

Ca Greater Curvature of Stomach ¹²

Ca Lesser Curvature - Stomach ¹²

Malignant Neoplasm of Stomach ⁷³

Gastric Cancer Intestinal ⁷⁵

Gastric Cancer, Somatic ⁵⁷

Adult Stomach Carcinoma ⁵³

Cancer of the Stomach ¹²

Carcinoma of Stomach ¹²

Adult Stomach Cancer ⁵³

Ca Body - Stomach ¹²

Gastric Neoplasm ¹²

Cancer, Gastric ⁴⁰

Gasc ⁷⁵

Characteristics:

HPO:

³²

gastric cancer:
Inheritance somatic mutation

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of stomach

Malignant neoplasm: Body of stomach

Malignant neoplasm: Greater curvature of stomach, unspecified

Malignant neoplasm: Lesser curvature of stomach, unspecified

Malignant neoplasm: Stomach, unspecified

External Ids:

OMIM ⁵⁷ 613659

Disease Ontology ¹² DOID:10534 DOID:5517

ICD10 ³³ C16 C16.2 C16.5 more

ICD9CM ³⁵ 151 151.4 151.5 more

MeSH ⁴⁴ D013274

NCIt ⁵⁰ C3387 C9331 C4911

MedGen ⁴² C0699791 C3150911

KEGG ³⁷ H00018

SNOMED-CT via HPO ⁶⁹ 124975008

UMLS ⁷³ C0024623 C0038356 C0153421 more

Sources

Summaries for Gastric Cancer

NIH Rare Diseases : ⁵³ Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial." Although the underlying cause of some familial cases is unknown, genetic changes (mutations) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and colorectal cancer, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Gastric Cancer is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Cyramza and Herceptin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are stomach cancer and increased level of l-fucose in urine

OMIM : ⁵⁷ In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659)

UniProtKB/Swiss-Prot : ⁷⁵ Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

MedlinePlus : ⁴³ The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

Disease Ontology : ¹² A gastrointestinal system cancer that is located in the stomach.

Wikipedia : ⁷⁶ Stomach cancer, also known as gastric cancer, is cancer developing from the lining of the stomach. Early... more...

Sources

Related Diseases for Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)

#	Related Disease	Score	Top Affiliating Genes
1	gastric adenocarcinoma	34.6	APC ERBB2 FGFR2 KRAS PIK3CA
2	colorectal cancer	34.0	APC ERBB2 KRAS MIR106B MIR141 MIR145
3	breast cancer	33.8	APC ERBB2 FGFR2 KRAS MIR141 MIR145
4	prostate cancer	33.4	ERBB2 FGFR2 KLF6 KRAS MIR106B MIR141
5	lung cancer	33.2	ERBB2 FGFR2 IRF1 KRAS MIR141 MIR145
6	adenocarcinoma	33.2	APC ERBB2 FGFR2 KRAS PIK3CA
7	hepatocellular carcinoma	33.2	APC KRAS MIR106B MIR141 MIR145 MIR203A
8	pancreatic cancer	32.9	ERBB2 KRAS MIR203A MIR20A MIR21 MIR221
9	esophageal cancer	32.8	ERBB2 KRAS MIR203A MIR21 MIR34A PIK3CA
10	melanoma	32.5	MIR141 MIR200C MIR221 MIR27A MIR34A
11	cholangiocarcinoma	32.3	ERBB2 FGFR2 KRAS MIR141 MIR21 PIK3CA
12	glioma	32.1	ERBB2 MIR20A MIR21 MIR221 MIR25 MIR34A
13	familial adenomatous polyposis	32.0	APC KRAS MUTYH
14	dermatomyositis	31.9	MIR21 MIR221 MIR34A
15	pancreatic ductal adenocarcinoma	31.9	MIR141 MIR145 MIR203A MIR21 MIR221
16	colorectal adenoma	31.9	APC KRAS MUTYH
17	lung cancer susceptibility 3	31.8	APC ERBB2 KRAS PIK3CA
18	attenuated familial adenomatous polyposis	31.3	APC MUTYH
19	leukemia, acute myeloid	31.0	KRAS MIR21 MIR221 MIR27A
20	gastric cancer, hereditary diffuse	12.7
21	diffuse gastric cancer	12.4
22	microinvasive gastric cancer	12.2
23	stomach carcinoma in situ	12.1
24	epstein-barr virus-associated gastric carcinoma	12.1
25	ovarian cancer	12.0	ERBB2 KRAS MIR106B MIR141 MIR200C MIR21
26	carcinoma of stomach, salivary gland type	12.0
27	undifferentiated carcinoma of stomach	12.0
28	adamantinoma of long bones	11.9	APC ERBB2 KRAS MIR141 MIR200C PIK3CA
29	leukemia, chronic lymphocytic	11.9	KRAS MIR106B MIR141 MIR145 MIR21 MIR221
30	oral squamous cell carcinoma	11.9	MIR145 MIR200C MIR203A MIR21 MIR221 MIR27A
31	endometrial cancer	11.9	ERBB2 FGFR2 KRAS MIR200C MUTYH PIK3CA
32	kidney cancer	11.9	MIR106B MIR141 MIR200C MIR20A MIR21 MIR27A
33	glioblastoma	11.9	ERBB2 MIR21 MIR221 MIR25 MIR34A PIK3CA
34	bladder cancer	11.8	ERBB2 KRAS MIR145 MIR203A MIR21 MIR221
35	squamous cell carcinoma, head and neck	11.8	ERBB2 MIR141 MIR21 MIR221 PIK3CA
36	gastrointestinal system cancer	11.8	ERBB2 KRAS MUTYH PIK3CA
37	esophagus adenocarcinoma	11.8	ERBB2 MIR145 MIR21 PIK3CA
38	ovarian serous carcinoma	11.7	MIR141 MIR145 MIR21 MIR27A
39	medulloblastoma	11.7	APC ERBB2 MIR20A MIR34A PIK3CA
40	hyperplastic polyposis syndrome	11.7	APC KRAS MUTYH
41	nonalcoholic fatty liver disease	11.7	MIR200C MIR203A MIR27A MIR34A
42	mutyh-associated polyposis	11.7	APC KRAS MUTYH
43	leukemia, acute lymphoblastic	11.7	MIR203A MIR21 MIR221 MIR27A
44	acneiform dermatitis	11.7	ERBB2 KRAS PIK3CA
45	adenosquamous cell lung carcinoma	11.7	ERBB2 KRAS PIK3CA
46	intestinal benign neoplasm	11.7	APC KRAS MUTYH
47	ovarian cancer 1	11.6	ERBB2 KRAS PIK3CA
48	malignant ovarian surface epithelial-stromal neoplasm	11.6	ERBB2 KRAS PIK3CA
49	ovary epithelial cancer	11.6	ERBB2 KRAS PIK3CA
50	endometrial adenocarcinoma	11.6	ERBB2 FGFR2 KRAS

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)

Active Peptic Ulcer Disease	Acute Cystitis
Deficiency Anemia	Gastric Fundus Cancer
Heart Disease	Intestinal Obstruction
Iron Deficiency Anemia	Neutropenia
Protein-Energy Malnutrition	Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:

Sources

Symptoms & Phenotypes for Gastric Cancer

Clinical features from OMIM:

613659

Human phenotypes related to Gastric Cancer:

³²

#	Description	HPO Frequency	HPO Source Accession
1	stomach cancer ³²		HP:0012126
2	increased level of l-fucose in urine ³²		HP:0410067

UMLS symptoms related to Gastric Cancer:

abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.17	APC ERBB2 FGFR2 IRF1 KRAS MUTYH

Sources

Drugs & Therapeutics for Gastric Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Cyramza ¹⁸ ⁴⁹	RAMUCIRUMAB	Eli Lilly	April 2014
FDA Label: Cyramza Disease/s that Drug Treats:gastric cancer Indications and Usage: ¹⁸ CYRAMZAÂ® is a human vascular endothelial growth factor receptor 2antagonist indicated as a single agent or in combination with paclitaxel, for treatmentof advanced gastric or gastro-esophageal junctionadenocarcinoma, with disease progression on or after priorfluoropyrimidine- or platinum-containing chemotherapy. (1.1) in combination with docetaxel, for treatment of metastatic nonsmallcell lung cancer with disease progression on or afterplatinum-based chemotherapy. Patients with EGFR or ALKgenomic tumor aberrations should have disease progression onFDA-approved therapy for these aberrations prior to receivingCYRAMZA. (1.2) in combination with FOLFIRI, for the treatment of metastaticcolorectal cancer with disease progression on or after priortherapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.(1.3) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: ligand-stimulated activation of VEGF Receptor 2 Action: inhibitor FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulatedactivation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of humanendothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
2	Herceptin ¹⁸ ⁴⁹	TRASTUZUMAB	Genentech	October 1998
FDA Label: Herceptin Disease/s that Drug Treats:Breast cancer/gastric cancer Indications and Usage: ¹⁸ Herceptin is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer (1.1, 1.2). the treatment of HER2-overexpressing metastatic gastric orgastroesophageal junction adenocarcinoma (1.3) DrugBank Targets: ¹⁶ 1. Receptor tyrosine-protein kinase erbB-2;2. Epidermal growth factor receptor;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. Low affinity immunoglobulin gamma Fc region receptor III-B;13. Low affinity immunoglobulin gamma Fc region receptor III-A Mechanism of Action: ¹⁸ Target: human epidermal growth factor receptor 2 protein (HER2) Action: binds with strong affinity for immune response FDA: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.
3	Iressa ¹⁸ ⁴⁹	GEFITINIB	AstraZeneca	May 2003
FDA Label: Iressa Disease/s that Drug Treats:Non-Small-Cell Lung Cancer Indications and Usage: ¹⁸ IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced ormetastatic non-small cell lung cancer after failure of both platinum-based and docetaxelchemotherapies who are benefiting or have benefited from IRESSA.In light of positive survival data with other agents including another oral EGFR inhibitor, physiciansshould use other treatment options in advanced non-small cell lung cancer patient populations whohave received one or two prior chemotherapy regimens and are refractory or intolerant to their mostrecent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICALPHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate anincrease in survival have been unsuccessful. Specifically, results from a large placebo-controlledrandomized trial in patients with advanced NSCLC who progressed while receiving or within 90 daysof the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, didnot show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studiessection).Results from two large, controlled, randomized trials in first-line treatment of non-small cell lungcancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy. , IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. In light of positive survival data with other agents including another oral EGFR inhibitor, physicians should use other treatment options in advanced non-small cell lung cancer patient populations who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies section). Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy. DrugBank Targets: ¹⁶ 1. Epidermal growth factor receptor, Epidermal growth factor receptor Mechanism of Action: ¹⁸ Target: EGFR tyrosine kinase and other tyrosine kinases, EGFR tyrosine kinase Action: inhibitor FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinibinhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembranecell surface receptors, including the tyrosine kinases associated with the epidermal growth factorreceptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.No clinical studies have been performed that demonstrate a correlation between EGFR receptorexpression and response to gefitinib., The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFR receptor expression and response to gefitinib.

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 555)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Capecitabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

61825-94-3

5310940 9887054 43805 6857599

Trastuzumab

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

180288-69-1

9903

Bevacizumab

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

216974-75-3

Amoxicillin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

26787-78-0

33613

Clarithromycin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

81103-11-9

84029

Esomeprazole

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

161796-78-7, 119141-88-7

4594 9579578

Levofloxacin

Approved, Investigational

Phase 4,Phase 3,Phase 1

100986-85-4

149096

Ofloxacin

Approved

Phase 4,Phase 3,Phase 1

82419-36-1

4583

Pravastatin

Approved

Phase 4

81093-37-0

54687

Aspirin

Approved, Vet_approved

Phase 4

50-78-2

2244

Clopidogrel

Approved

Phase 4

120202-66-6, 113665-84-2

60606

Pantoprazole

Approved

Phase 4,Not Applicable

102625-70-7

4679

Ticlopidine

Approved

Phase 4

55142-85-3

5472

Ecabet

Approved, Investigational

Phase 4

33159-27-2, 86408-72-2

65781

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

12035

Dexlansoprazole

Approved, Investigational

Phase 4,Phase 3,Not Applicable

138530-94-6, 103577-45-3

9578005

Lansoprazole

Approved, Investigational

Phase 4,Phase 3,Not Applicable

103577-45-3

3883

Famotidine

Approved

Phase 4,Phase 1

76824-35-6

3325

Histamine

Approved, Investigational

Phase 4,Phase 1,Not Applicable

75614-87-8, 51-45-6

774

Metronidazole

Approved

Phase 4,Phase 3,Phase 1

443-48-1

4173

Omeprazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

73590-58-6

4594

Etomidate

Approved

Phase 4

33125-97-2

36339 667484

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

437-38-7

3345

Propofol

Approved, Investigational, Vet_approved

Phase 4,Not Applicable

2078-54-8

4943

Somatostatin

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

38916-34-6, 51110-01-1

53481605

Fluorouracil

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

51-21-8

3385

Irinotecan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

97682-44-5, 100286-90-6

60838

Levoleucovorin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

68538-85-2

Iron

Approved

Phase 4,Phase 3,Not Applicable

7439-89-6

23925

Tinidazole

Approved, Investigational

Phase 4,Phase 3

19387-91-8

5479

Zinc

Approved, Investigational

Phase 4,Phase 2

7440-66-6

23994

Floxuridine

Approved

Phase 4,Phase 3,Phase 2,Phase 1

50-91-9

5790

Magnesium Sulfate

Approved, Investigational, Vet_approved

Phase 4,Phase 3

7487-88-9

24083

Simethicone

Approved

Phase 4

8050-81-5

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Ropivacaine

Approved

Phase 4,Phase 3,Not Applicable

84057-95-4

71273 175805

Dexmedetomidine

Approved, Vet_approved

Phase 4,Phase 3,Not Applicable

113775-47-6

68602 5311068

Coal tar

Approved

Phase 4

8007-45-2

Tetracycline

Approved, Vet_approved

Phase 4,Phase 3

60-54-8

5353990

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4,Phase 2

51-61-6, 62-31-7

681

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

942 89594

Rabeprazole

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

117976-89-3

5029

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

93-14-1

3516

Furazolidone

Approved, Investigational, Vet_approved

Phase 4

67-45-8

3435 5323714

Loperamide

Approved

Phase 4,Not Applicable

53179-11-6

3955

Pectin

Approved, Investigational, Vet_approved

Phase 4

9000-69-5

441476

Doxycycline

Approved, Investigational, Vet_approved

Phase 4,Phase 3

564-25-0

54671203

Tocopherol

Approved, Investigational, Nutraceutical

Phase 4,Phase 3,Not Applicable

1406-66-2

14986

Interventional clinical trials:

(show top 50) (show all 1759)

#	Name	Status	NCT ID	Phase	Drugs
1	Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery	Unknown status	NCT00757640	Phase 4
2	A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy	Unknown status	NCT02776527	Phase 4	Apatinib Mesylate Tablets
3	Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients	Unknown status	NCT01910948	Phase 4	omega-3 polyunsaturated fatty acids
4	Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis	Unknown status	NCT02380131	Phase 4	Oxaliplatin plus Capecitabine;Herceptin
5	Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis	Unknown status	NCT01962376	Phase 4	Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
6	Early Jejunostomy Nutrition Minimizes Time to Chemotherapy	Unknown status	NCT01766765	Phase 4
7	Community-based Helicobacter Pylori Eradication	Unknown status	NCT00155389	Phase 4	Helicobacter pylori eradication
8	Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer	Unknown status	NCT01038154	Phase 4	Pravastatin
9	Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?	Unknown status	NCT01621451	Phase 4	aspirin and/or clopidogrel;aspirin and/or clopidogrel
10	Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery	Unknown status	NCT01819961	Phase 4	MCT/LCT and fish oil;MCT/LCT
11	Effect of Helicobacter Pylori on the Availability of Vitamin E and C	Unknown status	NCT00303160	Phase 4	vitamin C & E supplements
12	Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection	Unknown status	NCT01308177	Phase 4	Ecabet
13	Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection	Unknown status	NCT02249546	Phase 4	N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
14	Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia	Unknown status	NCT00978159	Phase 4	esomeprazole;Famotidine
15	14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication	Unknown status	NCT01464060	Phase 4	PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
16	Optimizing Influenza Vaccination in Surgical Oncology Patients	Unknown status	NCT01698177	Phase 4
17	Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice	Unknown status	NCT01273441	Phase 4	PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
18	Combined Use of Etomidate and Propofol in Painless Gastroscopy.	Unknown status	NCT01913054	Phase 4	Fentanyl Injection;Etomidate Fat Emulsion Injection;Propofol Injection
19	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer	Unknown status	NCT00274885	Phase 4	oxaliplatin
20	Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection	Completed	NCT01914692	Phase 4	Somatostatin
21	RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients	Completed	NCT01401075	Phase 4	mistletoe extract;doxifluridine
22	Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor	Completed	NCT01579071	Phase 4
23	The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study	Completed	NCT02235246	Phase 4	Magnesium Sulfate;Normal saline
24	Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy	Completed	NCT01653171	Phase 4	Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
25	Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia	Completed	NCT01471756	Phase 4
26	Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy	Completed	NCT02458573	Phase 4
27	Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-	Completed	NCT01234272	Phase 4	morphine;Ropivacaine
28	The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy	Completed	NCT02164448	Phase 4	the dexmedetomidine group;the control group
29	Standard and Immunostimulating Enteral Nutrition in Surgical Patients	Completed	NCT00576940	Phase 4	Reconvan;Peptisorb
30	The Impact of Immunostimulating Nutrition on the Outcome of Surgery	Completed	NCT00558155	Phase 4	peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
31	Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection	Completed	NCT00656968	Phase 4	10-day sequential treatment;10-day concomitant therapy
32	The Effect of Nutritional Counseling for Cancer Patients	Completed	NCT01962272	Phase 4
33	Intraluminal Therapy for Helicobacter Pylori Infection	Completed	NCT03124420	Phase 4	Lansoprazole;Amoxicillin;Clarithromycin
34	10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection	Completed	NCT02959255	Phase 4	Esomeprazole
35	The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study	Completed	NCT00885417	Phase 4	Cravit-based sequential therapy
36	Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori	Completed	NCT01042184	Phase 4	Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
37	The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection	Completed	NCT01032655	Phase 4	susceptibility test guided sequential therapy
38	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
39	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
40	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Completed	NCT03384511	Phase 4	Apatinib
41	Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality	Recruiting	NCT02047994	Phase 4	Triple therapy
42	Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer	Recruiting	NCT02401971	Phase 4	Thalidomide;CPT-11
43	Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.	Recruiting	NCT02638584	Phase 4	Ilaprazole;Rabeprazole
44	Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer	Recruiting	NCT02426034	Phase 4	Apatinib
45	Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations	Recruiting	NCT03475589	Phase 4	apatinib
46	Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer	Recruiting	NCT02366819	Phase 4	Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
47	Laparoscopic Versus Open Resection of Cancer Stomach	Recruiting	NCT02789826	Phase 4
48	Iron Replacement in Oesophagogastric Neoplasia	Recruiting	NCT01927328	Phase 4	Iron isomaltoside 1000
49	Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection	Recruiting	NCT03521726	Phase 4	Amoxicillin;Rabeprazole, Amoxicillin
50	Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection	Recruiting	NCT03516669	Phase 4	Clarithromycin;Amoxicillin, Clarithromycin

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

cisplatin

cisplatin pwdr

docetaxel

floxuridine

fluorouracil

ifosfamide

irinotecan

irinotecan hydrochloride

methotrexate

methotrexate sodium

Cochrane evidence based reviews: stomach neoplasms

Sources

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

#	Genetic test	Affiliating Genes
1	Neoplasm of Stomach ²⁹	APC CASP10 ERBB2 FGFR2 IRF1 KLF6 MUTYH PIK3CA
2	Stomach Cancer ²⁹

Sources

Anatomical Context for Gastric Cancer

MalaCards organs/tissues related to Gastric Cancer:

⁴¹

Lymph Node, Liver, Lung, Testes, Breast, Endothelial, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

¹⁹

The Stomach

Sources

Publications for Gastric Cancer

Articles related to Gastric Cancer:

(show top 50) (show all 11066)

#	Title	Authors	Year
1	Risk Factors for Anastomotic Leakage of Esophagojejunostomy after Laparoscopy-Assisted Total Gastrectomy for Gastric Cancer. ( 28441658 )	Oshi M....Endo I.	2018
2	Isolated breast metastasis from gastric cancer in a male patient. ( 29302921 )	Kubo H....Niino H.	2018
3	GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. ( 29183726 )	Wang Y....Sun X.	2018
4	VDR independent induction of acid-sphingomyelinase by 1,23(OH)<sub>2</sub>D<sub>3</sub>in gastric cancer cells: Impact on apoptosis and cell morphology. ( 29158006 )	Albi E....Codini M.	2018
5	Overexpression of NEK3 is associated with poor prognosis in patients with gastric cancer. ( 29504992 )	Cao Y....Wu C.	2018
6	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. ( 29706558 )	Fewings E....Tischkowitz M.	2018
7	Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand MA8ori. ( 29589180 )	Hakkaart C....Guilford P.	2018
8	Role of germline aberrations affecting<i>CTNNA1</i>,<i>MAP3K6</i>and<i>MYD88</i>in gastric cancer susceptibility. ( 29330337 )	Weren R.D.A....Ligtenberg M.J.L.	2018
9	MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. ( 29054762 )	Zhou Y....Wang H.B.	2018
10	Superficial Spreading-type Gastric Cancer with <i>Situs Inversus Totalis</i>. ( 29695579 )	Namikawa T....Hanazaki K.	2018
11	Upregulation of ZBTB7A exhibits a tumor suppressive role in gastric cancer cells. ( 29207095 )	Sun G....Liang X.	2018
12	Discriminating gastric cancer and gastric ulcer using human plasma amino acid metabolic profile. ( 29626382 )	Jing F....Zhu Z.	2018
13	Inhibition of two gastric cancer cell lines induced by fucoxanthin involves downregulation of Mcl-1 and STAT3. ( 29110251 )	Yu R.X....Liu Z.	2018
14	Human epidermal growth factor receptor 2 expressions and Janus-activated kinase/signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway may be associated with clinicopathological features and prognosis of gastric cancer. ( 29970682 )	Xu W....Sun W.	2018
15	Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer. ( 29271006 )	Fu M....Zhang X.	2018
16	DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways. ( 29976242 )	Du F....Fan D.	2018
17	Impact of SNP-SNP interactions of DNA repair gene<i>ERCC5</i>and metabolic gene<i>GSTP1</i>on gastric cancer/atrophic gastritis risk in a Chinese population. ( 29434449 )	Sang L....Yuan Y.	2018
18	FBXO31 Suppresses Gastric Cancer EMT by Targeting Snail1 for Proteasomal Degradation. ( 29117943 )	Zou S....Liu Z.	2018
19	Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. ( 29306868 )	Rugge M....Genta R.M.	2018
20	Robot-assisted distal gastrectomy with lymph node dissection for gastric cancer in a patient with situs inversus partialis: a case report with video file. ( 29441475 )	Aisu Y....Hori T.	2018
21	Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer. ( 29106391 )	Song S.H....Kim T.Y.	2018
22	STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. ( 29329543 )	Chen J.F....Yang F.	2018
23	SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. ( 28962925 )	Chen L.Z....Xu R.H.	2018
24	The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer. ( 29090670 )	Gurzu S....Jung I.	2018
25	Association between density of tumor-infiltrating lymphocytes and prognoses of patients with gastric cancer. ( 29979429 )	Yu P.C....Zhang S.	2018
26	Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). ( 29189914 )	Chen S.C....Li C.	2018
27	LncRNA SNHG12 regulates gastric cancer progression by acting as a molecular sponge of miRa89320. ( 29207106 )	Zhang H....Lu W.	2018
28	Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. ( 29329569 )	Macalindong S.S....Kim Y.W.	2018
29	MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway. ( 29045821 )	Li L....Deng J.	2018
30	Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth. ( 29435734 )	Ye J....Lin X.	2018
31	miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway. ( 29185784 )	Wang P....Qiu W.	2018
32	miR-135b-5p promotes gastric cancer progression by targeting CMTM3. ( 29345297 )	Lu M....Li L.	2018
33	Overexpression of lncRNA LINC01793 acts as a potential predictor for progression and poor prognosis of gastric cancer. ( 29978448 )	Huang S....Chen L.	2018
34	BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC. ( 28681984 )	Ba M....Cui S.	2018
35	PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. ( 29034543 )	Mimura K....Kono K.	2018
36	Gastrectomy with limited surgery for elderly patients with gastric cancer. ( 27693065 )	Mikami K....Maekawa T.	2018
37	Screening Biomarker as an Alternative to Endoscopy for the Detection of Early Gastric Cancer: The Combination of Serum Trefoil Factor Family 3 and Pepsinogen. ( 29977284 )	Lee H.S....Yang H.M.	2018
38	A novel design of HA-coated nanoparticles co-encapsulating plasmid METase and 5-Fu shows enhanced application in targeting gastric cancer stem cells. ( 29016350 )	Yang W....Xin L.	2018
39	Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study. ( 28648576 )	Leung W.K....Wu C.Y.	2018
40	ASSOCIATION OF INTERLEUKIN-10 -1082 A/G (RS1800896) POLYMORPHISM WITH SUSCEPTIBILITY TO GASTRIC CANCER: META-ANALYSIS OF 6,101 CASES AND 8,557 CONTROLS. ( 29561974 )	Namazi A....Neamatzadeh H.	2018
41	Case report about a successful full robotic radical gastric cancer surgery with intracorporeal robot-sewn anastomosis in a patient with situs inversus totalis and a two-and-a-half-year follow-up study. ( 29499701 )	Dai H.B....Jiang Z.W.	2018
42	BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells. ( 29393385 )	Lian G....Chen M.	2018
43	Lysyl oxidase activates cancer stromal cells and promotes gastric cancer progression: quantum dot-based identification of biomarkers in cancer stromal cells. ( 29343955 )	Peng C....Li Y.	2018
44	Hereditary diffuse gastric cancer: how to look for and how to manage it. ( 29869323 )	Polom K....Roviello F.	2018
45	Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. ( 29465762 )	Yoshioka T....Toyooka S.	2018
46	Health Barriers and Patterns of Gastric Cancer Care in Rural Central American Resource-Limited Settings. ( 29978182 )	Estevez-Ordonez D....Morgan D.R.	2018
47	Molecular and Pathological Features of Gastric Cancer in Lynch Syndrome and Familial Adenomatous Polyposis. ( 29882764 )	Fornasarig M....Cannizzaro R.	2018
48	Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT. ( 29443079 )	Shi B....Zhang H.	2018
49	Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging? ( 29971670 )	Lin J.X....Li P.	2018
50	G9A promotes gastric cancer metastasis by upregulating ITGB3 in a SET domain-independent manner. ( 29449539 )	Hu L....Zhu Z.G.	2018

Sources

Genes for Gastric Cancer

Genes related to Gastric Cancer (30 elite genes):

(show top 50) (show all 230)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	APC	APC, WNT Signaling Pathway Regulator	Protein Coding	1360.72	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁵ Genetic Tests ²⁹ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Pathways & Interactions Variants (show sections)	1317264 23852704 12378616 (more) 8732100 9639793 20025482 9990480 10408833 10692769 19336228 12373147 11304579 16075282 8855982 7559732 11819821 15639864 11756228 8406987 7676688 11399952 18069630 15942635 11243597 15083323 17693665 9808525
2	CASP10	Caspase 10	Protein Coding	1358.17	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁵ Genetic Tests ²⁹ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	12010812 11973654 23852704 (more) 15288293 11973654 20025484 14714615
3	MUTYH	MutY DNA Glycosylase	Protein Coding	1355.73	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁵ Genetic Tests ²⁹ Pathogenic/Likely pathogenic ⁶ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Variants (show sections)	15273732 23852704 16929514 (more) 15273732 18776649 18383848 15180946 19998059
4	IRF1	Interferon Regulatory Factor 1	Protein Coding	1337.75	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁵ Genetic Tests ²⁹ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	9679752 23852704 19697121 (more) 9679752
5	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	1056.24	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	15016963 15520168 15608678 (more) 17673550 22658544 22729222 23852704 22729224 22729223 15608678 12569555 15784156 17680560 17935137 19062713
6	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	1034.33	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	10394936 11325814 23852704 (more) 11325814 16391783 18381441 17459342 20331976 1844251 10626794 18636142 7791773 15796961 19387476 17697126 17505008 16773196 7562911 16273224 15754011 12684685 12739007 19212647 8205545 12684693
7	KLF6	Kruppel Like Factor 6	Protein Coding	1019.8	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)	15824733 23852704
8	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	765.75	Pathogenic ⁶ Causative variation ⁷⁵ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Pathways & Interactions Variants (show sections)	8439212 7773929 20805368 (more) 22683711 20949522 22499344 17332249 21079152 23852704 16187281 15994075 16007118 19545448 19639197 9301460 17697521 19013893 14534542 20358631 19755509
9	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	712.29	Molecular basis known ⁵⁷ Genetic Tests ²⁹ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Pathways & Interactions Functions Variants (show sections)	15457249 23852704 20424000 (more) 10829039 9164544 16546744 12143229 7889468 16328035 12530043 7902202 17088902 9703936 11796015 20522955 19636613 15649431 10920922 20038315 18422971 8397058 9892105 19269014 18097546 18441328 14520697 1577221 12548420 1670998 19956838 10754464 20443098 20185938 12739007 12679307 16868827 11857411 10679740 14719064 14535591 15363548 20331976 15501972 16406575 16077916 19337752 8643220 7734322 20368841 20208134 20164030 18258606 8099338 15646832 9544434 7991990 16490596 14991576 1355336 1379062 19156142 7842412 12810831 11776569 17031648 16949920 16718853 11837710 9088037 15668283 11399867 10809364 9732228 7676688 11032920 18224443 16632435 8095412 18483367 16309427 14618618 10950153 9136822 9387254 7912666 8104420 7907612 19536776 19628076 11322480 9758367 9428926 7528080 19783961 16328600 16273224 16121348 9765619 8412172 8102619 1358410 10393360 10223227 9602330 7911025 20082479 17555797 12490974 1350646 19061514 1673870 7901825 1352299 8093216 15517369 7993593 11680933 9058162 7907854 11948459 11396210 15928192 1353880 7907434 1979253 19034345 11776853 8098198 1970690 2157713 1346086 12579211 2098274 18835621 18413839 9570245 2386738 19479974 18172343 8330300 1350789 10619912 7882346 8103127 1676988 20430735 12692839 1348293 10446693 9927058 7753016 16187281 10618628 7775839 8697969 9275549
10	MIR21	MicroRNA 21 Using TaqMan quantitative real-time PCR, we confirmed that miR-21 was significantly overexpressed in human gastric cancer tissues and cell lines. Remarkably, miR-21 was also significantly overexpressed in H. pylori-infected gastric mucosa, implying that overexpression of miR-21 in gastric cancer may be due in part to H. pylori infection. More importantly, we showed that forced expression of miR-21 significantly enhanced cell proliferation and invasion in AGS cells, a human gastric cancer cell line, whereas knockdown of miR-21 by inhibitor caused a significant reduction in cell proliferation and a significant increase in apoptosis. Furthermore, we demonstrated that knockdown of miR-21 significantly decreased cell invasion and migration of AGS cells. Finally, we showed that RECK, a known tumor suppressor in gastric cancer, is a bona fide target of miR-21. Taken together, miR-21 may be important in the initiation and progression of gastric cancers as an oncomiR, likely through regulating RECK. Our findings suggest a potential regulatory pathway in which H. pylori infection upregulates expression of miR-21, which in turn downregulates RECK, and then leads to the development of gastric cancer.	RNA Gene	407.75	Causal ⁴⁷ Unspecified ⁴⁷ GeneCards inferred via : Publications (show sections)	18794849 16461460
11	MIR25	MicroRNA 25 Although it has been speculated that the miRNAs in the same cluster may play related biological functions, this has not been experimentally addressed. Here we report that the miRNAs in two clusters (miR-106b approximately 93 approximately 25 and miR-222 approximately 221) suppress the Cip/Kip family members of Cdk inhibitors (p57(Kip2), p21(Cip1) and p27(Kip1)). We show that miR-25 targets p57 through the 3'-UTR. Furthermore, miR-106b and miR-93 control p21 while miR-222 and miR-221 regulate both p27 and p57. Ectopic expression of these miRNAs results in activation of Cdk2 and facilitation of G1/S phase transition. Consistent with these results, both clusters are abnormally upregulated in gastric cancer tissues compared to the corresponding normal tissues. Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model. Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters.	RNA Gene	407.07	Causal ⁴⁷ Unspecified ⁴⁷ GeneCards inferred via : Publications (show sections)	19153141 16461460
12	MIR221	MicroRNA 221 Although it has been speculated that the miRNAs in the same cluster may play related biological functions, this has not been experimentally addressed. Here we report that the miRNAs in two clusters (miR-106b approximately 93 approximately 25 and miR-222 approximately 221) suppress the Cip/Kip family members of Cdk inhibitors (p57(Kip2), p21(Cip1) and p27(Kip1)). We show that miR-25 targets p57 through the 3'-UTR. Furthermore, miR-106b and miR-93 control p21 while miR-222 and miR-221 regulate both p27 and p57. Ectopic expression of these miRNAs results in activation of Cdk2 and facilitation of G1/S phase transition. Consistent with these results, both clusters are abnormally upregulated in gastric cancer tissues compared to the corresponding normal tissues. Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model. Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters.	RNA Gene	407	Causal ⁴⁷ Unspecified ⁴⁷ GeneCards inferred via : Publications (show sections)	19153141 16461460
13	MIR34A	MicroRNA 34a miR-34a up-regulated in the gastric cancer patients compared to the control subjects. Mir-34a had been shown to be dysregulated in malignant GC tissues.	RNA Gene	357.53	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	21112772
14	MIR200C	MicroRNA 200c miRNA-200c can indirectly regulate apoptosis through E-cadherin in SGC7901/DDP cells, which may be a possible mechanism of miRNA-200c in reversing drug resistance and inhibiting proliferation. The miRNA-200c expression in SGC7901/DDP cells after transfection of Pre-200c was 7.128 ± 0.159 times of that in negative control (P	RNA Gene	357.23	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	21114921
15	MIR141	MicroRNA 141 MiR-141 was significantly down-regulated in 80% (28/35) of primary gastric cancer tissues compared with pair-matched adjacent non-tumor tissues (P	RNA Gene	357.23	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	19363643
16	MIR27A	MicroRNA 27a It was investigated the possible role of a common A/G polymorphism (rs895819) within hsa-mir-27a in the development or progression of gastric cancer, and assessed the effect of rs895819 on the expression of miR-27a and its target gene Zinc finger and BTB domain containing 10 (ZBTB10). In the present case-control study, it was found that subjects with the variant genotypes (AG + GG) showed a significantly increased risk of gastric cancer relative to AA carriers (adjusted odds ratio = 1.48, 95% confidence interval 1.06-2.05; P = 0.019).	RNA Gene	357.23	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	20666778
17	MIR145	MicroRNA 145 The expression levels of miR-143 and -145 were decreased in most human gastric cancers examined, as previously reported to occur in colon tumors. The transfection of human gastric MKN-1 cells with miR-145 resulted in a greater growth inhibitory effect than that with miR-143, results which were contrary to those in colon cancers. In MKN-1 cells, an additive effect on growth inhibition was shown by the combined transfection with miR-143 and miR-145; further, higher sensitivity to 5-fluorouracil was also observed following the transfection with miR-143 or miR-145. The possible candidate target messenger RNAs of miR-145 were identified to be insulin receptor substrate-1 and beta-actin. Conclusion: Taken together, these findings suggest that miR-143 and miR-145 act as anti-oncomirs common to gastrointestinal tumors.	RNA Gene	357.23	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	19439999
18	MIR106B	MicroRNA 106b miR-106b-25 cluster, upregulated in a subset of human gastric tumors, is activated by E2F1 in parallel with its host gene, Mcm7. In turn, miR-106b and miR-93 regulate E2F1 expression, establishing a miRNA-directed negative feedback loop. Furthermore, upregulation of these miRNAs impairs the TGFbeta tumor suppressor pathway, interfering with the expression of CDKN1A (p21(Waf1/Cip1)) and BCL2L11 (Bim).	RNA Gene	357.13	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	18328430
19	MIR203A	MicroRNA 203a Although expression of miR-203 was not significant in gastric cancer tissues (p?=?0.124), interestingly, miR-203 was correlated with tumor size (p?=?0.023), macroscopic type (p?=?0.045), and pT stage (p?=?0.013). Furthermore, it was found miR-203 can inhibit the cell proliferation in SGC-7901 cells.	RNA Gene	357.07	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	21063914
20	MIR20A	MicroRNA 20a miR-20a up-regulated in the gastric cancer patients compared to the control subjects. Mir-20a had been shown to be dysregulated in malignant GC tissues.	RNA Gene	357.07	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	21112772
21	MIR222	MicroRNA 222 Although it has been speculated that the miRNAs in the same cluster may play related biological functions, this has not been experimentally addressed. Here we report that the miRNAs in two clusters (miR-106b approximately 93 approximately 25 and miR-222 approximately 221) suppress the Cip/Kip family members of Cdk inhibitors (p57(Kip2), p21(Cip1) and p27(Kip1)). We show that miR-25 targets p57 through the 3'-UTR. Furthermore, miR-106b and miR-93 control p21 while miR-222 and miR-221 regulate both p27 and p57. Ectopic expression of these miRNAs results in activation of Cdk2 and facilitation of G1/S phase transition. Consistent with these results, both clusters are abnormally upregulated in gastric cancer tissues compared to the corresponding normal tissues. Ectopic expression of miR-222 cluster enhanced tumor growth in the mouse xenograft model. Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters.	RNA Gene	357.07	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	19153141
22	MIR143	MicroRNA 143 The expression levels of miR-143 and -145 were decreased in most human gastric cancers examined, as previously reported to occur in colon tumors. The transfection of human gastric MKN-1 cells with miR-145 resulted in a greater growth inhibitory effect than that with miR-143, results which were contrary to those in colon cancers. In MKN-1 cells, an additive effect on growth inhibition was shown by the combined transfection with miR-143 and miR-145; further, higher sensitivity to 5-fluorouracil was also observed following the transfection with miR-143 or miR-145. The possible candidate target messenger RNAs of miR-145 were identified to be insulin receptor substrate-1 and beta-actin. Conclusion: Taken together, these findings suggest that miR-143 and miR-145 act as anti-oncomirs common to gastrointestinal tumors.	RNA Gene	357	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	19439999
23	MIR215	MicroRNA 215 Luciferase assays suggested that microRNA-215 inhibits activated leukocyte cell adhesion molecule (ALCAM) expression at the posttranscriptional level. In addition, expression levels of ALCAM were significantly lower in gastric carcinomas (GC) than in non-neoplastic stomach (NS). MicroRNA-215 is overexpressed in vivo and exert cell growth and migration-promoting effects in vitro, thus representing potential microRNA-215 with a role in cancer in the human stomach.	RNA Gene	356.84	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	21119604
24	MIR451A	MicroRNA 451a Down-regulation of miR-451 was associated with worse prognosis. miR-451 was detected by in situ hybridization in epithelial cells and showed decreased expression in gastric and colorectal cancer versus nontumoral tissues. Overexpression of miR-451 in gastric and colorectal cancer cells reduced cell proliferation and increased sensitivity to radiotherapy. Microarray and bioinformatic analysis identified the novel oncogene macrophage migration inhibitory factor (MIF) as a potential target of miR-451. In fact, overexpression of miR-451 down-regulated mRNA and protein levels of MIF and decreased expression of reporter genes with MIF target sequences. Moreover, we found a significant inverse correlation between miR-451 and MIF expression in tumoral gastric biopsies. CONCLUSIONS: These findings support the role of miR-451 as a regulator of cancer proliferation and open new perspectives for the development of effective therapies for chemoradioresistant cancers.	RNA Gene	356.84	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	19318487
25	MIR93	MicroRNA 93 miR-106b-25 cluster, upregulated in a subset of human gastric tumors, is activated by E2F1 in parallel with its host gene, Mcm7. In turn, miR-106b and miR-93 regulate E2F1 expression, establishing a miRNA-directed negative feedback loop. Furthermore, upregulation of these miRNAs impairs the TGFbeta tumor suppressor pathway, interfering with the expression of CDKN1A (p21(Waf1/Cip1)) and BCL2L11 (Bim).	RNA Gene	356.72	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	18328430
26	MIR192	MicroRNA 192 Expression levels of both microRNA-192 was significantly higher in gastric cancer (GC) than in NS (P	RNA Gene	350	Causal ⁴⁷	21119604
27	MIR196B	MicroRNA 196b This study showed that the expression of miR-196b was significantly elevated in gastric cancers compared with its adjacent normal tissues through hypomethylating its promoter regions. It was found that the lack of promoter methylation in the miR-196b may lead to its overexpression in a majority of gastric cancers. Considering the high frequency of miR-196b promoter hypomethylation found in gastric cancer, miR-196b overexpression could provide a useful tumor marker.	RNA Gene	350	Causal ⁴⁷	20662076
28	MIR15B	MicroRNA 15b In vitro drug sensitivity assay demonstrated that overexpression of miR-15b or miR-16 sensitized SGC7901/VCR cells to anticancer drugs whereas inhibition of them using antisense oligonucleotides conferred SGC7901 cells MDR. The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein. Enforced mir-15b or miR-16 expression reduced Bcl-2 protein level and the luciferase activity of a BCL2 3' untranslated region-based reporter construct in SGC7901/VCR cells, suggesting that BCL2 is a direct target of miR-15b and miR-16. Moreover, overexpression of miR-15b or miR-16 could sensitize SGC7901/VCR cells to VCR-induced apoptosis.	RNA Gene	350	Causal ⁴⁷	18449891
29	MIR150	MicroRNA 150 miR-150 was up-regulated in gastric cancer compared to normal ones. Forced expression of miR-150 promoted the growth of gastric cancer cells in a series of proliferation assays both in vitro and in vivo. By bioinformatics analysis, it was identified the tumor-suppressor EGR2 as a putative miR-150 target. Subsequent experiments confirmed that up-regulation of miR-150 repressed the expression of EGR2, which occurred at the translational level.	RNA Gene	350	Causal ⁴⁷	20067763
30	MIR122	MicroRNA 122 Restoration of APC function in colorectal cancer cells led to the deregulation of several cancer-related microRNAs, such as miR-122a which was recognized as the liver-specific microRNA. MiR-122a was down-regulated in gastrointestinal cancer cell lines as well as primary carcinoma tissues. Inhibition of miR-122a could reverse wild-type APC-induced growth inhibition of gastrointestinal cancer cells while miR-122a mimic inhibited cell growth. In summary, we identified some cancer-related microRNAs regulated by APC/beta-catenin signaling pathway. The down-regulation of miR-122a mediated by aberrant APC/beta-catenin signaling is important to the pathogenesis of gastrointestinal cancers.	RNA Gene	350	Causal ⁴⁷	19607815
31	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming We identified an lncRNA-AF147447 decreased expressed by H. pylori infection, which can inhibit GC proliferation and invasion in vitro and in vivo, act as a tumor suppressor in the development of H. pylori induced GC. Dysfunction Pattern: Expression [low expression]	Protein Coding	207.33	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	27835575 15378790 19329938 (more) 16820924 10604660 20062084 9308730 15248919 17387567 15637340 15807306 18573283 7515385 16185290 11278696 14742272 15086835 17559374 15737028 14758553 11745219 15354218 11775866 16733847 16988760 12498221 10681391 11889602 18938748 12719460 9583726 10620506 19102008 16807756 11574777 20492327 18521835 14719100 12692839 11101634 18507055 17213039 14525978 10699992 15309883 10592051 12490305 15071739 14636271 14576935
32	GACAT2	Gastric Cancer Associated Transcript 2 Compared with healthy individuals, plasma GACAT2 levels were significantly increased in patients with GD (P<0.001) and preoperative patients with GC (P=0.040). Moreover, the individual relative changes of plasma GACAT2 expression following surgery were significantly associated with lymphatic metastasis (P=0.034), distal metastasis (P=0.035) and perineural invasion (P=0.039). Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	166.72	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications Gene name (show sections)	28105191
33	GACAT3	Gastric Cancer Associated Transcript 3 AC130710 in gastric cancer was significantly higher. Its expression level was significantly associated with tumor size,tumor-node-metastasis (TNM) stages,and distal metastasis. miR-129-5p may play an important role in the downregulation of AC130710 in gastric cancer cells. These results indicated that lncRNA-AC130710 may be a potential tumor marker for gastric cancer prognosis. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	166.67	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications Gene name (show sections)	27644247
34	FRGCA	FOXM1-Regulated, Gastric Cancer Associated The downregulation of LncRNA-AP001631.9 by small interference RNA suppressed the migratory ability of MGC803 and AGS cells,while the overexpression of LncRNA-AP001631.9 promoted the movement of BGC823 and SGC7901 cells. Furthermore,a tail vein injection was administered,and the obtained results suggested that LncRNA-AP001631.9 contributed to the distant metastasis of SGC7901 cells.Our findings established that LncRNA-AP001631.9 plays critical roles in gastric cancer progression and can serve as a potential new target for the treatment of gastric cancer. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	166.19	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications Gene name (show sections)	26261500
35	HOTAIR	HOX Transcript Antisense RNA Dioscin inhibits gastric tumor growth through regulating the expression level of lncRNA HOTAIR. Dysfunction Pattern: Regulation	RNA Gene	165.81	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)	28970725
36	LINC00673	Long Intergenic Non-Protein Coding RNA 673 In this study, we found that lncRNA LINC00673 is significantly upregulated in gastric cancer. Knockdown of LINC00673 inhibited cell proliferation and invasion and induced cell apoptosis, whereas LINC00673 overexpression had the opposite effect. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	165.77	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications Summaries (show sections)	28214253
37	FENDRR	FOXF1 Adjacent Non-Coding Developmental Regulatory RNA FENDRR was downregulated in gastric cancer cell lineand cancerous tissues,as compared with normal gastric epithelial cells and adjacent noncancerous tissue samples. Low FENDRR expression was correlated with deeper tumor invasion,higher tumor stage,and lymphatic metastasis. Histone deacetylation was involved in the downregulation of FENDRR in gastric cancer cells. FENDER overexpression suppressed invasion and migration by gastric cancer cells in vitro,by downregulating FN1 and MMP2/MMP9 expression. Dysfunction Pattern: Regulation [down-regulated]	RNA Gene	165.77	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications Summaries (show sections)	25167886
38	CCAT1	Colon Cancer Associated Transcript 1 CCAT1 is up-regulated in GC and may be significantly correlated with the progression of GC. Decreased expression of CCAT1 can suppress the proliferation of GC cells. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	165.38	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)	26825578
39	EGFLAM-AS1	EGFLAM Antisense RNA 1 Significantly reduced expression of lncRNA-LOWEG was found in gastric tissues and cell line(SGC-7901,AGS,BGC-823 and HG-27) compared with patient-matched nontumorous adjacent tissues (P < 0.01) or the normal gastric cell line GES-1 (P < 0.05). Lastly,western blot and real-time PCR analysis suggested that lncRNA-LOWEG is positively correlated with the expression of leukemia inhibitory factor receptor (LIFR) gene at the translational level. Dysfunction Pattern: Regulation [down-regulated]	RNA Gene	165.02	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications Gene name (show sections)	26537802
40	YAP1	Yes Associated Protein 1 YAP1 over-expression promoted the proliferation, migration, and invasion of human immortalized normal gastric mucosa GES-1 cells in vitro by reversing the above signal molecules. Dysfunction Pattern: Expression [overexpression]	Protein Coding	164.86	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)	27835600
41	GHET1	Gastric Carcinoma Proliferation Enhancing Transcript 1 In the clinical analyzing, compared with adjacent tissues, the pathological was significantly changed in tumor tissues, the GHET1 gene and protein expressions were significantly increased in the GC tissues. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	161.91	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ ¹⁵	28577495
42	GAPLINC	Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA Long Noncoding RNA GAPLINC Regulates CD44-Dependent Cell Invasiveness and Associates with Poor Prognosis of Gastric Cancer. Dysfunction Pattern: Regulation	RNA Gene	161.31	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ ¹⁵	25277524
43	TUG1	Taurine Up-Regulated 1 Expression of PlncRNA-1 and TUG1 were significantly upregulated in GC tumoral tissues, and significantly correlated with clinicopathological characters. However, FAM83H-AS1 showed no consistently differential expression. The expression of these three long noncoding RNAs was significantly higher in The Cancer Genome Atlas tumoral tissues. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	159.8	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	27983921
44	SNHG8	Small Nucleolar RNA Host Gene 8 For all gastric cancers, SNHG8 expression was 14 times higher (P=0.001) than that in non-cancer controls; in the EB virus related gastric cancers, SNHG8 expression was increased 25 times (P<0.05) over EB virus negative gastric cancers. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	159.42	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ ¹⁵	28173665
45	H19	H19, Imprinted Maternally Expressed Transcript H19 expression was up-regulated and closely related to TNM cancer stages in GC patients. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	159.31	Experimental evidence: Regulation ³⁹ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	28105222 9570380
46	LINC01234	Long Intergenic Non-Protein Coding RNA 1234 We found that LINC01234 expression was significantly upregulated in gastric cancer tissues and was associated with larger tumor size, advanced TNM stage, lymph node metastasis, and shorter survival time. Furthermore, knockdown of LINC01234-induced apoptosis and growth arrest in vitro and inhibited tumorigenesis in mouse xenografts. Mechanistic investigations indicated that LINC01234 functioned as a ceRNA for miR-204-5p, thereby leading to the derepression of its endogenous target core-binding factor ? (CBFB).Conclusions: LINC01234 is significantly overexpressed in gastric cancer, and LINC01234-miR-204-5p-CBFB axis plays a critical role in gastric cancer tumorigenesis. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	158.12	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ ¹⁵	29386218
47	RIOX2	Ribosomal Oxygenase 2 Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma,esophageal squamous cell carcinoma,and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma. Dysfunction Pattern: Expression [differentially expressed]	Protein Coding	157.44	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵ ¹⁵	24757675
48	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1 MALAT1 is thought to regulate tumor cell viability, invasiveness and migration Dysfunction Pattern: Regulation	RNA Gene	157.18	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	28396617
49	UCA1	Urothelial Cancer Associated 1 The long non-coding RNA UCA1 was upregulated in HRGC cells, which promoted their migration. Bioinformatics analysis and a luciferase reporter assay showed that miR-7-5p could bind to specific sites of UCA1 to regulate the target EGFR through competitive endogenous RNA function. UCA1 directly interacted with miR-7-5p and decreased the binding of miR-7-5p to the EGFR 3'-untranslated region, which suppressed the degradation of EGFR mRNA by miR-7-5p. Therefore, long-term hypoxia induced UCA1 to promote cell migration by enhancing the expression of EGFR. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	157.13	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	29723509
50	CYTOR	Cytoskeleton Regulator RNA Our results revealed that miR-139-5p inhibited glycolysis by regulating AMP-activated, alpha 1 catalytic subunit (PRKAA1) expression in gastric cancer cells. We also found that miR-139-5p was down-regulated by long intergenic non-coding RNA 152 (LINC00152) in gastric cancer cells. Dysfunction Pattern: Regulation	RNA Gene	157.07	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	29156518

Sources

Variations for Gastric Cancer

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

⁷⁵ (show all 19)

#	Symbol	AA change	Variation ID	SNP ID
1	APC	p.Gly817Cys	VAR_005035
2	APC	p.Ile880Thr	VAR_005036
3	APC	p.Asn942Asp	VAR_005039
4	APC	p.Gly1120Glu	VAR_005042	rs28933379
5	APC	p.Arg1171His	VAR_005043	rs372481703
6	APC	p.Phe1197Ser	VAR_005045
7	APC	p.Ile1259Thr	VAR_005046
8	APC	p.Gly1312Glu	VAR_005050
9	APC	p.Val1326Ala	VAR_005052
10	CASP10	p.Met147Thr	VAR_037428	rs121909776
11	IRF1	p.Met8Leu	VAR_065134	rs121912469
12	IRF1	p.Trp11Arg	VAR_065135	rs121912470
13	KRAS	p.Gly12Val	VAR_006840	rs121913529
14	KRAS	p.Gly12Asp	VAR_016026	rs121913529
15	KRAS	p.Gly12Ser	VAR_016028

Gastric Cancer

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Characteristics:

HPO:

Classifications:

External Ids:

Summaries for Gastric Cancer

Related Diseases for Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)

Graphical network of the top 20 diseases related to Gastric Cancer:

Symptoms & Phenotypes for Gastric Cancer

Clinical features from OMIM:

Human phenotypes related to Gastric Cancer:

UMLS symptoms related to Gastric Cancer:

MGI Mouse Phenotypes related to Gastric Cancer:

Drugs & Therapeutics for Gastric Cancer

FDA approved drugs:

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: stomach neoplasms

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

Anatomical Context for Gastric Cancer

MalaCards organs/tissues related to Gastric Cancer:

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

Publications for Gastric Cancer

Articles related to Gastric Cancer:

Genes for Gastric Cancer

Genes related to Gastric Cancer (30 elite genes):

Variations for Gastric Cancer

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :